FDA News

FDA approves CV risk indication for semaglutide

January 17, 2020
The FDA on Thursday approved a new indication for the GLP-1 receptor agonist semaglutide to reduce the risk for major adverse cardiovascular events…
In the Journals

In AF, obstructive sleep apnea confers stroke risk

January 17, 2020
Among patients with atrial fibrillation, obstructive sleep apnea was an independent risk factor for major adverse CV and neurologic events…
Meeting NewsPerspective

Dapagliflozin may improve lung fluid volume in HF

January 17, 2020
PHILADELPHIA — Treatment with the SGLT2 inhibitor dapagliflozin was not associated with a reduction in mean lung fluid volume among adults with…
In the Journals

BP elevations occur earlier in life for women vs. men

January 16, 2020
BP elevations occurred more rapidly in women compared with men and as early as the third decade of life, which may explain why CVD presents at…
Perspective

CDC: More than 15% of US adults physically inactive

January 16, 2020
More than 15% of adults in every U.S. state and territory are physically inactive, according to new CDC data. “Too many adults are inactive…
In the Journals

Region-specific gaps persist in acute HF management

January 16, 2020
Patients from several regions across the world present similarly with acute HF, but differences were observed regarding the type and timing of…
In the Journals

Malignant LV hypertrophy may help explain elevated HF incidence in black population

January 16, 2020
Malignant left ventricular hypertrophy, a subtype in which patients have elevations in cardiac biomarkers associated with risk for HF, is more common…
Feature

Q&A: Additional therapies for secondary prevention may be effective, but also expensive

January 16, 2020
Results of a 5-year estimate showed that up to 20% of CV events could be prevented if patients with ischemic heart disease or MI received additional…
Trial Scorecards

WRAP-IT

Cardiology Today, January 2020
Impact of major cardiac implantable electronic device infections on mortality and other outcomes.
Meeting NewsPerspective

Twice-yearly inclisiran reduces LDL in ASCVD, FH

Cardiology Today, January 2020
Inclisiran, an investigational cholesterol-lowering therapy, reduced LDL in high-risk patients with atherosclerotic CVD and in those with…
Trial Scorecards

RECOVERY

Cardiology Today, January 2020
Early surgery vs. conventional treatment strategy in patients with very severe aortic stenosis.
Trial Scorecards

PIONEER-OLE

Cardiology Today, January 2020
Safety and efficacy of mavacamten (MyoKardia) in patients with obstructive hypertrophic cardiomyopathy.
Cover Story

New use for an old drug: The potential of colchicine in CVD

Cardiology Today, January 2020
Secondary prevention of CVD with colchicine is a major focus for the cardiology community, especially after recent presentations of the COLCOT and…
Trial Scorecards

MEMS-HF

Cardiology Today, January 2020
Use of CardioMEMS HF System (Abbott) in a real-world setting.

Key opinion leaders discuss top news from 2019

Cardiology Today, January 2020
Approximately 50% of high school students are vaping. The major product in these devices is nicotine, one of the most addicting substances known. As…
Trial Scorecards

FRANCE-TAVI

Cardiology Today, January 2020
Balloon-expandable compared with self-expanding transcatheter aortic valves in patients with native aortic stenosis.
Commentary

Differences in dyslipidemia guidelines underscore complexity of CVD prevention

Cardiology Today, January 2020
Ethan Tumarkin, MD, PhD; Marc Engels, MD, PhD; Seth S. Martin, MD, MHS; Rhanderson Cardoso, MD
The use of lipid-lowering therapy has been a hallmark of CV risk reduction for several decades. The cornerstone of CV prevention is risk assessment…
Trial Scorecards

COSMIC-HF

Cardiology Today, January 2020
Omecamtiv mecarbil (Amgen) vs. placebo to increase contractility in patients with HF.
Trial Scorecards

COACT

Cardiology Today, January 2020
Immediate vs. delayed coronary angiography in patients indicated for PCI.
Trial Scorecards

CLOSE TO CURE

Cardiology Today, January 2020
Atrial tachyarrhythmia burden before vs. after close-guided pulmonary vein isolation in patients with paroxysmal AF.